CN105683195B - 喹啉取代的化合物 - Google Patents

喹啉取代的化合物 Download PDF

Info

Publication number
CN105683195B
CN105683195B CN201480058192.XA CN201480058192A CN105683195B CN 105683195 B CN105683195 B CN 105683195B CN 201480058192 A CN201480058192 A CN 201480058192A CN 105683195 B CN105683195 B CN 105683195B
Authority
CN
China
Prior art keywords
amino
bases
quinoline
compound
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480058192.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105683195A (zh
Inventor
宇野贵夫
野野下克昌
岛村整
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CN105683195A publication Critical patent/CN105683195A/zh
Application granted granted Critical
Publication of CN105683195B publication Critical patent/CN105683195B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201480058192.XA 2013-08-22 2014-08-22 喹啉取代的化合物 Active CN105683195B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013172746 2013-08-22
JP2013-172746 2013-08-22
PCT/JP2014/071951 WO2015025936A1 (ja) 2013-08-22 2014-08-22 新規キノリン置換化合物

Publications (2)

Publication Number Publication Date
CN105683195A CN105683195A (zh) 2016-06-15
CN105683195B true CN105683195B (zh) 2017-11-10

Family

ID=52483707

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480058192.XA Active CN105683195B (zh) 2013-08-22 2014-08-22 喹啉取代的化合物

Country Status (21)

Country Link
US (2) US9650386B2 (https=)
EP (1) EP3037424B1 (https=)
JP (1) JP6161705B2 (https=)
KR (1) KR101906688B1 (https=)
CN (1) CN105683195B (https=)
AU (1) AU2014309788B2 (https=)
BR (1) BR112016003247B1 (https=)
CA (1) CA2922077C (https=)
DK (1) DK3037424T3 (https=)
ES (1) ES2656712T3 (https=)
HU (1) HUE034807T2 (https=)
MX (1) MX370808B (https=)
MY (1) MY182891A (https=)
NO (1) NO3037424T3 (https=)
PH (1) PH12016500225B1 (https=)
PL (1) PL3037424T3 (https=)
PT (1) PT3037424T (https=)
RU (1) RU2689158C2 (https=)
SG (1) SG11201600759XA (https=)
TW (1) TWI603971B (https=)
WO (1) WO2015025936A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037424B1 (en) * 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
IL266239B2 (en) * 2016-10-31 2023-10-01 Taiho Pharmaceutical Co Ltd A selective inhibitor of EGFR with an EXON 20 insertion mutation
MA46852A (fr) * 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
FR3068971B1 (fr) * 2017-07-12 2019-08-30 Protneteomix Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer
HUE066587T2 (hu) * 2017-09-01 2024-08-28 Taiho Pharmaceutical Co Ltd Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor
IL284330B2 (en) * 2018-12-28 2026-03-01 Taiho Pharmaceutical Co Ltd EGFR inhibitor resistant to treatment mutant L718 and/or L792
AU2020240382B2 (en) 2019-03-19 2022-08-25 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
US12157730B2 (en) 2019-03-19 2024-12-03 Voronoi Inc. Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
WO2021057796A1 (zh) * 2019-09-29 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
US20230372346A1 (en) * 2020-09-08 2023-11-23 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
JP2024523861A (ja) 2021-06-15 2024-07-02 ジェネンテック， インコーポレイテッド がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用
CN115707704B (zh) * 2021-08-20 2024-09-13 广东医诺维申生物技术有限公司 氘代稠合三环类化合物及其组合物和用途
JP2025538804A (ja) * 2022-12-08 2025-11-28 アッシア ケミカル インダストリーズ リミテッド ジパレルチニブの固体状態の形態及びそれを調製するための方法
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
EP4722218A1 (en) 2023-05-31 2026-04-08 Taiho Pharmaceutical Co., Ltd. Crystal of quinoline-substituted compound
WO2025141465A1 (en) 2023-12-27 2025-07-03 Assia Chemical Industries Ltd. Solid state forms of zipalertinib hydrochloride and process for preparation thereof
WO2025167588A1 (zh) * 2024-02-05 2025-08-14 苏州科睿思制药有限公司 Zipalertinib的晶型及其制备方法和用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130903A (zh) * 1994-05-20 1996-09-11 大鹏药品工业株式会社 稠合的1，2-二氢化茚及其可药用盐
CN101175755A (zh) * 2005-03-17 2008-05-07 诺瓦提斯公司 作为酪氨酸/苏氨酸激酶抑制剂特别是b－raf激酶的n－[3－(1－氨基－5,6,7,8－四氢－2,4,4b－三氮杂芴－9－基)－苯基]苯甲酰胺
WO2011046964A2 (en) * 2009-10-12 2011-04-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN102471335A (zh) * 2009-07-10 2012-05-23 大鹏药品工业株式会社 氮杂二环式化合物或其盐
WO2012093708A1 (ja) * 2011-01-07 2012-07-12 大鵬薬品工業株式会社 新規二環式化合物又はその塩
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
WO2013100014A1 (ja) * 2011-12-28 2013-07-04 大鵬薬品工業株式会社 抗腫瘍剤の効果増強剤
WO2013118817A1 (ja) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351863B (es) * 2012-02-23 2017-10-30 Taiho Pharmaceutical Co Ltd Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
EP2960241A4 (en) 2013-02-22 2016-07-13 Taiho Pharmaceutical Co Ltd PROCESS FOR PREPARING TRICYCLIC COMPOUNDS AND TRICYCLIC COMPOUNDS MADE ACCORDING TO THE SAID MANUFACTURING METHOD
EP3037424B1 (en) * 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130903A (zh) * 1994-05-20 1996-09-11 大鹏药品工业株式会社 稠合的1，2-二氢化茚及其可药用盐
CN101175755A (zh) * 2005-03-17 2008-05-07 诺瓦提斯公司 作为酪氨酸/苏氨酸激酶抑制剂特别是b－raf激酶的n－[3－(1－氨基－5,6,7,8－四氢－2,4,4b－三氮杂芴－9－基)－苯基]苯甲酰胺
CN102471335A (zh) * 2009-07-10 2012-05-23 大鹏药品工业株式会社 氮杂二环式化合物或其盐
WO2011046964A2 (en) * 2009-10-12 2011-04-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2012093708A1 (ja) * 2011-01-07 2012-07-12 大鵬薬品工業株式会社 新規二環式化合物又はその塩
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
WO2013100014A1 (ja) * 2011-12-28 2013-07-04 大鵬薬品工業株式会社 抗腫瘍剤の効果増強剤
WO2013118817A1 (ja) * 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩

Also Published As

Publication number Publication date
ES2656712T3 (es) 2018-02-28
CA2922077C (en) 2018-06-26
EP3037424B1 (en) 2017-11-08
PH12016500225A1 (en) 2016-05-02
PT3037424T (pt) 2017-12-18
US9758526B2 (en) 2017-09-12
CN105683195A (zh) 2016-06-15
KR101906688B1 (ko) 2018-10-10
HK1222393A1 (zh) 2017-06-30
PL3037424T3 (pl) 2018-03-30
EP3037424A1 (en) 2016-06-29
DK3037424T3 (en) 2017-12-11
MX370808B (es) 2020-01-07
RU2019114688A (ru) 2020-07-29
RU2689158C2 (ru) 2019-05-24
RU2016110096A (ru) 2017-09-27
SG11201600759XA (en) 2016-03-30
CA2922077A1 (en) 2015-02-26
MY182891A (en) 2021-02-05
NO3037424T3 (https=) 2018-04-07
WO2015025936A1 (ja) 2015-02-26
AU2014309788A1 (en) 2016-03-10
TW201542547A (zh) 2015-11-16
BR112016003247A2 (https=) 2017-08-01
JP6161705B2 (ja) 2017-07-12
PH12016500225B1 (en) 2016-05-02
US20160194332A1 (en) 2016-07-07
EP3037424A4 (en) 2017-01-25
KR20160043114A (ko) 2016-04-20
US20170101414A1 (en) 2017-04-13
JPWO2015025936A1 (ja) 2017-03-02
AU2014309788B2 (en) 2017-02-16
TWI603971B (zh) 2017-11-01
US9650386B2 (en) 2017-05-16
RU2016110096A3 (https=) 2018-06-18
HUE034807T2 (en) 2018-02-28
MX2016002125A (es) 2016-06-28
BR112016003247B1 (pt) 2022-05-10

Similar Documents

Publication Publication Date Title
CN105683195B (zh) 喹啉取代的化合物
CN104136438B (zh) 喹啉基吡咯并嘧啶基稠环化合物或其盐
WO2013118817A1 (ja) キノリルピロロピリミジン化合物又はその塩
HK1222393B (en) Quinoline-substituted compound
RU2797117C2 (ru) Новое хинолин-замещенное соединение
HK1202862B (en) Quinolylpyrrolopyrimidyl fused-ring compound or salt thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222393

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1222393

Country of ref document: HK